Jeroen Goede
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Fürstenau M, Thus Y, Robrecht S, Mellink C, van der Kevie-Kersemaekers A, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber P, Tadmor T, Levin M, da Cunha-Bang C, Schneider C, Poulsen C, Illmer T, Schöttker B, Janssens A, Christiansen I, Noesslinger T, Baumann M, Hebart H, Gaska T, Regelink J, Dompeling E, Lindstrom V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink A, Fischer K, Wendtner C, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann C, Hallek M, Eichhorst B, Kreuzer K, Kater A. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. Blood 2023
12.05.2023High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
12.05.2023Blood 2023
Fürstenau Moritz, Thus Yvonne J, Robrecht Sandra, Mellink Clemens H M, van der Kevie-Kersemaekers Anne-Marie F, Dubois Julie, von Tresckow Julia, Patz Michaela, Gregor Michael, Thornton Patrick, Staber Philipp B, Tadmor Tamar, Levin Mark-David, da Cunha-Bang Caspar, Schneider Christof, Poulsen Christian Bjørn, Illmer Thomas, Schöttker Björn, Janssens Ann, Christiansen Ilse, Noesslinger Thomas, Baumann Michael, Hebart Holger, Gaska Tobias, Regelink Josien, Dompeling Ellen C, Lindstrom Vesa, Juliusson Gunnar, Widmer Anouk Andrea, Goede Jeroen, Goldschmidt Neta, Simon Florian, De Silva Nisha, Fink Anna Maria, Fischer Kirsten, Wendtner Clemens-Martin, Ritgen Matthias, Brüggemann Monika, Tausch Eugen, Spaargaren Marcel, Eldering Eric, Stilgenbauer Stephan, Niemann Carsten Utoft, Hallek Michael, Eichhorst Barbara, Kreuzer Karl-Anton, Kater Arnon P
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia 2023; 37:699-701.
12.01.2023Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
12.01.2023Leukemia 2023; 37:699-701
Zander Thilo, Pabst Thomas, Schär Sämi, Aebi Stefan, Mey Ulrich J M, Novak Urban, Lerch Erika, Rhyner Agocs Gaëlle, Goede Jeroen, Maniecka Zuzanna, Hayoz Stefanie, Rüfer Axel, Renner Christoph, Driessen Christoph
Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).
Rüfer A, Angermann H, Benz R, Bonadies N, Calderoni A, Cantoni N, Efthymiou A, Escher R, Favre G, Friess D, Gschwend A, Himmelmann A, Holbro A, Keller P, Kouroupi E, Lehmann T, Pedarnig N, Rigamonti V, Samii K, Schmidt A, Schäfer H, Sperb R, Stussi G, Winkler A, Zenhäusern R, Goede J. Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q). Hemasphere 2022; 6:e741.
17.06.2022Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).
17.06.2022Hemasphere 2022; 6:e741
Rüfer Axel, Angermann Hubert, Benz Rudolf, Bonadies Nicolas, Calderoni Antonello, Cantoni Nathan, Efthymiou Anna, Escher Robert, Favre Geneviève, Friess Dorothea, Gschwend Andreas, Himmelmann Andreas, Holbro Andreas, Keller Peter, Kouroupi Eirini, Lehmann Thomas, Pedarnig Nikolaus, Rigamonti Véronique, Samii Kaveh, Schmidt Adrian, Schäfer Hans-Peter, Sperb Roland, Stussi Georg, Winkler Annette, Zenhäusern Reinhard, Goede Jeroen